Primary safety end point achieved for Onglyza?

摘要

AstraZeneca and Bristol-Myers Squibb recently announced results from the SAVOR trial that patients with Type 2 diabetes who are at high risk of cardiovascular events had no increased risk of cardiovascular death, nonfatal myocardial infarction or nonfatal ischemic stroke when Onglyza? (saxagliptin) was added to their current treatment regimen.